Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT is a gene therapy-focused biotech company developing therapeutic candidates using its proprietary vector platform (lead programs 4D-150 and 4D-710).
|
$599.35M |
$10.50
+4.37%
|
|
PSNL
Personalis, Inc.
NeXT Personal is a tumor-informed liquid biopsy-based MRD test, central to PSNL's offerings.
|
$597.65M |
$6.72
+0.90%
|
|
BWAY
BrainsWay Ltd.
Core product: BrainsWay's Deep TMS neuromodulation devices.
|
$597.46M |
$15.85
+3.39%
|
|
ASPI
ASP Isotopes Inc. Common Stock
ASPI’s PET Labs Radiopharmaceuticals production and enriched isotopes are delivered as a core product line.
|
$595.21M |
$5.38
+5.28%
|
|
CTKB
Cytek Biosciences, Inc.
Cytek's instrument manufacturing includes flow cytometry diagnostic equipment, the core product line referenced in the article.
|
$589.46M |
$4.61
|
|
RIGL
Rigel Pharmaceuticals, Inc.
Rigel's core products are oncology/hematology therapies (TAVALISSE, REZLIDHIA, GAVRETO), fitting Biotech - Oncology.
|
$588.65M |
$32.39
+1.95%
|
|
PRTA
Prothena Corporation plc
Prothena's core assets are monoclonal antibody therapeutics (PRX012, PRX019, PRX123, etc.) across neurodegenerative diseases, including Alzheimer's and other indications.
|
$586.75M |
$10.88
+3.37%
|
|
CRMD
CorMedix Inc.
DefenCath is an FDA-approved antimicrobial catheter-lock device marketed by CorMedix.
|
$582.25M |
$7.39
+3.65%
|
|
TCMD
Tactile Systems Technology, Inc.
Core medical devices for lymphedema and airway clearance (Flexitouch Plus, Nimbl, AffloVest) are manufactured and sold by the company.
|
$574.69M |
$25.72
+2.35%
|
|
EMBC
Embecta Corp.
Embecta operates as a medical device company focused on insulin injection devices, including pen needles, syringes, and safety products.
|
$572.26M |
$9.80
+3.05%
|
|
BBNX
Beta Bionics, Inc.
Core product is a medical device (iLet Bionic Pancreas) and related biometrics in diabetes care.
|
$571.44M |
$12.99
+6.69%
|
|
MLAB
Mesa Laboratories, Inc.
Clinical Genomics hardware (MassARRAY) is diagnostic equipment used in regulated lab environments, fitting Diagnostic Equipment.
|
$569.13M |
$103.28
+4.59%
|
|
MG
Mistras Group, Inc.
MG provides Laboratory Testing & Advisory Services as part of its inspection and testing offerings.
|
$563.13M |
$17.82
+3.66%
|
|
TECX
Tectonic Therapeutic, Inc.
TX45 is a recombinant fusion protein (Fc-relaxin) developed using TECX's GEODe platform, fitting the Recombinant Proteins & Enzymes category.
|
$552.32M |
$29.46
-0.74%
|
|
RLMD
Relmada Therapeutics, Inc.
NDV-01 is Relmada's lead oncology candidate targeting non-muscle invasive bladder cancer (NMIBC).
|
$548.54M |
$7.48
+6.86%
|
|
KOPN
Kopin Corporation
CR3 medical headset and defense medical imaging/biometric sensing align with Medical Devices & Biometrics.
|
$543.89M |
$2.98
+1.19%
|
|
ENGN
enGene Holdings Inc.
engGene's core platform is non-viral gene therapy delivery (DDX platform) and its lead asset is a gene therapy product, placing it squarely in Gene Therapy.
|
$540.57M |
$8.04
-0.43%
|
|
UPB
Upstream Bio, Inc.
Verekitug is a monoclonal antibody therapeutic targeting the TSLP receptor, directly aligning with Monoclonal Antibody Therapeutics.
|
$539.85M |
$10.00
-0.99%
|
|
NPCE
NeuroPace, Inc.
Core product Neuromodulation device (RNS System) delivering brain-responsive, on-demand therapy for drug-resistant epilepsy.
|
$539.25M |
$16.20
+4.62%
|
|
ABSI
Absci Corporation
Absci's core platform is an Antibody Discovery Platform combining AI design with high-throughput wet-lab validation (lab-in-the-loop) for de novo antibody generation.
|
$538.33M |
$3.59
+11.15%
|
|
ALLO
Allogene Therapeutics, Inc.
Direct product category: off-the-shelf allogeneic CAR-T cell therapies (Allogene's core platform and pipeline).
|
$537.11M |
$2.38
+0.21%
|
|
TRDA
Entrada Therapeutics, Inc.
Entrata's primary value proposition is its Drug Delivery Platform (EEV) enabling intracellular delivery of therapeutics.
|
$534.69M |
$13.98
+3.10%
|
|
ZIMV
ZimVie Inc.
Dental Equipment—ZimVie directly designs and sells dental hardware used in clinics (implants, imaging, CAD/CAM, etc.).
|
$530.23M |
$18.99
|
|
ADCT
ADC Therapeutics S.A.
ADCT's lead product ZYNLONTA is an antibody-drug conjugate (ADC), directly aligning with the Antibody-Drug Conjugates category.
|
$530.19M |
$4.29
-2.05%
|
|
AQST
Aquestive Therapeutics, Inc.
Aquestive's PharmFilm drug-delivery platform enables non-invasive, thin-film administration of complex molecules; Anaphylm and Libervant employ this platform.
|
$527.05M |
$4.33
+1.64%
|
|
CYRX
Cryoport, Inc.
BioStorage/BioServices-like offerings place Cryoport in the realm of diagnostics/lab services and related bioservices for samples and storage.
|
$518.21M |
$10.36
+1.87%
|
|
ANNX
Annexon, Inc.
Annexon's lead programs are monoclonal antibody therapeutics (ANX005, ANX009) targeting C1q.
|
$515.37M |
$4.67
-6.87%
|
|
PACB
Pacific Biosciences of California, Inc.
PacBio directly manufactures diagnostic sequencing equipment (instruments) used in molecular diagnostics and research laboratories.
|
$510.22M |
$1.68
+3.07%
|
|
LYEL
Lyell Immunopharma, Inc.
Lyell’s lead program LYL314 is a CAR-T cell therapy product targeting cancer (CD19/CD20 dual-target), the core business.
|
$509.45M |
$23.98
+1.18%
|
|
MDXG
MiMedx Group, Inc.
Directly manufactures and sells wound care devices and placental tissue allografts (EPIFIX, EPICORD, EPIEFFECT) used in wound healing.
|
$505.77M |
$3.41
-0.58%
|
|
LXEO
Lexeo Therapeutics, Inc. Common Stock
Company is focused on AAV-based gene therapies (LX2006, LX2020) delivering therapeutic genes — direct Gene Therapy business.
|
$504.34M |
$6.90
+4.86%
|
|
OFIX
Orthofix Medical Inc.
Core product category covering orthopedic implants and surgical devices, including spinal hardware.
|
$503.31M |
$12.72
+2.66%
|
|
FLGT
Fulgent Genetics, Inc.
Company operates clinical lab chains providing diagnostic testing.
|
$502.64M |
$16.29
+0.99%
|
Showing page 17 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
